The present invention discloses a class of quinine compounds andpharmaceuticallyacceptable salts, solvates, prodrugs or optical isomers thereof Also disclosedin the presentinvention are that the above compounds have a selective antagonistic effect onthe receptorsubtypes of M1 and M3, but have no significant effect on M2 receptor subtype,and the abovecompounds are characterized by rapid action, long-lasting efficacy, and lowtoxic andside-effects when used to treat rhinitis, post-cold rhinitis, chronictrachitis, airwayhyperresponsiveness, asthma, chronic obstructive pulmonary diseases, cough,urinaryincontinence, frequent urination, unstable bladder syndrome, bladder spasms,bladderinflammation and gastrointestinal diseases such as irritable bowel syndrome,spastic colitis, aswell as duodenal and gastric ulcers.
